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Abstract
Objective To determine the extent and nature of selective non-reporting
of harm outcomes in clinical studies that were eligible for inclusion in a
cohort of systematic reviews.
Design Cohort study of systematic reviews from two databases.
Setting Outcome reporting bias in trials for harm outcomes (ORBIT II)
in systematic reviews from the Cochrane Library and a separate cohort
of systematic reviews of adverse events.
Participants 92 systematic reviews of randomised controlled trials and
non-randomised studies published in the Cochrane Library between
issue 9, 2012 and issue 2, 2013 (Cochrane cohort) and 230 systematic
reviews published between 1 January 2007 and 31 December 2011 in
other publications, synthesising data on harm outcomes (adverse event
cohort).
Methods A 13 point classification system for missing outcome data on
harm was developed and applied to the studies.
Results 86% (79/92) of reviews in the Cochrane cohort did not include
full data from the main harm outcome of interest of each review for all
of the eligible studies included within that review; 76% (173/230) for the
adverse event cohort. Overall, the single primary harm outcome was
inadequately reported in 76% (705/931) of the studies included in the
92 reviews from the Cochrane cohort and not reported in 47%
(4159/8837) of the 230 reviews in the adverse event cohort. In a sample
of primary studies not reporting on the single primary harm outcome in
the review, scrutiny of the study publication revealed that outcome
reporting bias was suspected in nearly two thirds (63%, 248/393).
Conclusions The number of reviews suspected of outcome reporting
bias as a result of missing or partially reported harm related outcomes
from at least one eligible study is high. The declaration of important
harms and the quality of the reporting of harm outcomes must be
improved in both primary studies and systematic reviews.
Introduction
“When we looked at that data, it actually showed an
increase in harm amongst those who got the active
treatment, and we ditched it because we weren’t
expecting it and we were concerned that the
presentation of these data would have an impact on
people’s understanding of the study findings.”1
Health technology assessment is a form of policy research that
examines evidence of safety, efficacy, and cost effectiveness
of a healthcare technology to provide guidance and
recommendations to support decisions about treatment. Health
technology assessment systematic reviews of clinical studies
aim to include all relevant studies conducted on a particular
topic and to provide an unbiased summary of their results, thus
producing the best evidence on the benefits and harms of
medical treatments. However, research has shown that the
validity of systematic reviews can be affected by outcome
reporting bias in the primary studies, which has been defined
as selection (on the basis of the results) of a subset of the original
variables recorded for inclusion in a study publication.2
The prevalence and impact of outcome reporting bias has
recently been investigated in a large unselected cohort of
Cochrane systematic reviews (ORBIT (OutcomeReporting Bias
In Trials) I study).3 This study, which focused on a single
primary outcome for each review, found that over half the
reviews (157/283, 55%) could not include data for the review
primary outcome from all eligible studies. Additionally,
interviews were conducted with trialists to understand the
reasons for discrepancies between outcomes specified in the
study protocol and those reported in the study publication.1 The
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main finding was that trialists had reported the outcomes in a
biased way in over a quarter of the studies.
The ORBIT I study focused primarily on selective non-reporting
bias for benefit outcomes. Empirical evidence suggests that the
reporting of data on harms is likely to be less complete than that
of efficacy measures.4 There are also many studies that have
previously measured poor adverse event reporting in primary
studies and systematic reviews, and all concluded that the
reporting of harm outcomes is problematic.5-7 Interviews with
trialists have revealed that in one instance important harm
outcomes were subject to selective non-reporting because the
trialists preferred to focus on the positive benefits of an
intervention, while leaving “undesirable” data on harms
unreported.1
In the current study, ORBIT II, we estimated the prevalence of
selective non-reporting of outcomes in studies within a cohort
of published meta-analyses, where the outcome was harm. We
developed a new classification system for the assessment of
selective non-reporting of harm outcomes, and we demonstrate
the application of this classification in two cohorts of systematic




We examined both an unselected cohort of new reviews from
the Cochrane Library (Cochrane cohort) and a separate cohort
of systematic reviews of adverse events (adverse event cohort).
Each month the Cochrane Library indexes newly published
reviews in each monthly issue as “new reviews.” PS identified
all new Cochrane reviews from six monthly issues (issue 9,
2012 to issue 2, 2013). For the adverse event cohort, we had
access to a bibliographic list of potentially eligible systematic
reviews of adverse effects that had previously been identified
and evaluated in other publications.8-10 In brief, two separate
researchers (YKL and other colleagues) checked all records that
were published between 2007 and 2011 in the Cochrane
Database of Systematic Reviews and the Database of Abstracts
of Reviews of Effects. A review was included in the
bibliographic list if the primary aim was to evaluate adverse
effects associated with any healthcare intervention (as stated in
the objectives of the review by the author).We excluded reviews
in which adverse effects were a secondary outcome or the
objective was to evaluate the “effectiveness and safety” of an
intervention. The two cohorts of reviews were therefore clearly
distinguishable; the Cochrane cohort typically consisted of
reviews that aimed to assess the beneficial and unintended
effects of an intervention within the same reviews. In contrast,
the adverse event cohort consisted of reviews that were designed
to focus on harms, and as such would have used search strategies
tailored towards identifying studies reporting on specific harms.
We included reviews that included exclusively randomised
controlled trials and a combination of randomised controlled
trials and non-randomised studies. We excluded reviews that
considered only non-randomised studies, methodological and
diagnostic test accuracy studies, and overviews of reviews.
Assessment of systematic reviews
For each review in the cohorts, JJK or PS examined the section
referring to types of outcome measures to determine whether
the review specified no harm outcome, harm outcomes pooled
together (for example, any adverse events or all adverse events),
or a specific harm outcome (for example, gastrointestinal
bleeding or heart failure). The lead reviewer was then contacted
and asked to confirm our categorisation and to select the single
most important harm outcome if multiple specific harms were
listed. Where no contact could be established, a clinical
professor in clinical pharmacology and co-convenor of the
Cochrane Adverse EffectsMethods Group (YKL) reviewed our
categorisations and where necessary selected a single primary
harm outcome from those listed. The supplementary figure and
table provide examples of reviews where the review did not
specifically evaluate harm outcomes, the single primary harm
outcome was clear from the review, the single primary harm
outcome had to be chosen by the reviewer or pharmacological
expert, and only pooled harms were specified.
We then further scrutinised the reviews where a single primary
harm outcome had been defined. Reviews that did not identify
any studies (empty review) were not assessed further. Equally,
reviews that specified no harm outcomes or reported only on
pooled harm outcomeswere excluded from further consideration
because an assessment of outcome reporting bias in these
situations would not be possible or feasible. Two investigators
(PS and JJK) scrutinised each review to check whether all
included studies fully reported the single primary harm outcome.
Reviews were also eligible for further assessment if any primary
studies had been excluded from the review for the single reason
of not reporting on any review outcomes of interest. This is
because potential outcome reporting bias can occur when a study
report does not mention or give results for particular outcomes;
absence of data on adverse effects does not necessarily mean
that such outcomes were not measured or analysed.We therefore
checked the list of excluded studies within a systematic review
and reasons for exclusion to see if a study had been
inappropriately excluded because the study did not report on
any of the relevant review outcomes. If the references to
excluded studies of interest were not provided by the reviews
(in the adverse event cohort), we contacted the lead authors for
clarification. If these study reports were not available on request,
then we excluded the review from further assessment because
a complete assessment could not be performed.
We selected a sample of 50 eligible reviews from each cohort
for further assessment. The 50 reviews were randomly sampled
from the list of eligible reviews that contained no more than 20
studies. This restriction was applied because the ORBIT I study
showed that review authors were less likely to respond if the
burden of work was too great; this typically arose when a review
included a large number of studies requiring assessment.
Classification of studies in the reviews
Full reporting
We considered full reporting to have taken place if outcome
data on the single primary harm outcome from the primary
studies had been included by reviewers in the review
meta-analysis (or tabulated in full if a meta-analysis was not
appropriate). Such outcome data may have been included in the
study report or indirectly calculated from the results. For binary
outcome data, we considered full reporting to have occurred if
the sample size was reported in each group together with either
the number of participants with the event for each group or the
odds ratio or relative risk with precise P value or a measure of
precision or variability (confidence interval or standard error).
For continuous outcome data, we judged that full reporting had
taken place if the study described group sample sizes and
magnitude of the treatment effect (for example, group means
or medians or mean differences), and an exact P value or a
measure of precision or variability (confidence interval, standard
deviation, or standard error). When data on the single primary
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harm outcome were missing or incompletely described in the
review, but detailed examination of the primary study showed
that the single primary harm outcome had actually been fully
reported, we classified this situation as full reporting. If data
were available (but somehow omitted from the review), we
provided feedback to review authors so that the data could be
included in an update of the review.
Not reported or partially reported
We developed a classification system to assess whether a study
had been excluded from a meta-analysis or the descriptive
analysis because the data for the harm outcome were either not
reported or only partially reported. The system was designed to
make a judgment about the reason for missing data on harm
outcomes and was refined over the initial few months of the
study. When any amendments were made, we reviewed all
previous classifications and adjusted them accordingly to ensure
consistency of application. The categories reflect the stages of
assessing whether a specific harm outcome was measured or
compared, and finally the nature of the results presented (table
1⇓).We used the category letters (P-V) to distinguish them from
the A-I classifications used for benefit outcomes in the ORBIT
I study.3 The classification systemwas designed to be used with
both randomised controlled trials and non-randomised studies.
A supplementary table provides examples and guidance of when
to use each of the ORBIT II classifications.
In the context of harm outcomes, we awarded classifications
for “high risk” outcome reporting bias when the specific harm
had been measured but the data were presented or suppressed
in a way that would mask the harm profile of particular
interventions (including providing detail on the seriousness of
the harms)—that is, P1, P2, R, and S classifications (table 1).
The reasoning behind this particular definition of bias is that in
all these situations we at least suspect that the harm outcome
had beenmeasured and thus the selective non-reporting or partial
reporting could have been driven by a biased related reason (for
example, higher frequency of harm in one treatment arm).
Missing data as a result of a P1, P2, R, or S classification are
also likely to have the biggest impact on the treatment effect in
a meta-analysis of reviews.
Using all the identified publications for a study, one investigator
(PS or JJK) classified any study that did not fully report the
review single primary harm outcome of interest. This also
involved evaluating excluded studies that had been selected for
assessment. Review authors were also contacted to answer any
queries and to provide their expert clinical judgments on the
classifications for each study. For each classification,
justification for the categorisation was recorded in prose to
supplement the category code, including verbatim quotes from
the study publication whenever possible. When the coauthors
of the corresponding review were unable to assist with our
assessments, an expert in adverse events (YKL) also completed
the assessment. This approach ensured that each assessment
had input from one clinical expert and one non-clinical
methodological expert. Any complex cases were discussed with
experts in trial design and management (DA, CG, or PRW) at
study group meetings. Discrepancies were discussed until a
final overall classification was agreed for each study and the
justification for the classification documented in full. To check
for consistency, at the end of the study JJK reviewed all agreed
classifications, with the justification. This additional quality
assurance step ensured that the same classification was awarded
to studies that had missing or partially reported data on harms
for the same reason. Supplementary figure A provides a
summary of the study methods.
Results
Description of review cohorts
Cochrane cohort
The Cochrane Library published 243 new reviews in issue 9,
2012 to issue 2, 2013 (fig 1⇓). Specific harm outcomes were
listed in 92 reviews, of which 16 identified a single primary
harm outcome in the review text. For the remaining 76 reviews,
lead reviewers, coauthors, or YKL selected a single primary
harm outcome from those specific harms listed (which happened
to be the first listed harm outcome in 55 (72%) of the reviews).
In the 92 reviews that aimed to assess specific harms, the median
number of studies per review was 7 (range 0-75, interquartile
range 3-12). A total of 13 reviews did not require further
assessment: eight did not identify any studies (empty review)
and five fully reported the single review primary harm outcome
for all eligible studies. Further assessment was required in the
remaining 79/92 reviews (86%) as they did not include full data
on the single review primary harm outcome from all eligible
studies.
Adverse event cohort
A total of 234 reviews published between 2007 and 2011 were
identified in the adverse event cohort (fig 2⇓). Specific harms
were listed in all but four reviews, where only pooled harms
were stated. A single primary harm outcomewas clearly defined
in the review text for 190 of the 230 reviews where specific
harms were stated. The single primary harm outcome for the
remaining 40 reviews was selected by lead reviewers, coauthors,
or YKL (this was the first listed harm outcome in 36 (90%)
reviews). In the 230 reviews specifying specific harms, the
median number of studies per review was 18 (range 1-209,
interquartile range 16-29). A total of 57 reviews did not require
further assessment as they fully reported the single review
primary harm outcome for all eligible studies. Further
assessment was required in the remaining 173/230 reviews
(76%) as they did not include full data on the single review
primary harm outcome from all eligible studies. However, a
complete assessment could only be done in about half of these
reviews (n=86) because citations of studies that were excluded
owing to “no relevant outcome data” were not provided in the
reference list of the review and were not obtainable from the
review authors.
Description of studies with missing single
primary harm outcome in review
We assessed the 92 reviews in the Cochrane cohort and found
that the review single primary harm outcome was partially
reported or not reported for 705 (76%) of the 931 studies
included (fig 3⇓). For the adverse event cohort, there were a
total of 8837 studies across all 230 reviews where a single
primary harm outcome was specified, 7720 of which were
implicated in the 173 reviews where further outcome reporting
bias assessment was required (fig 4⇓). Nearly half (47%,
4159/8837) of the studies did not report or had partially reported
the single primary harm outcome; only 796 of these were
included in the 86 reviews for which a complete assessment
could be carried out. References were unavailable for 2337
studies that were excluded owing to “no relevant data,” of which
the design of the study was unknown in 1637 (fig 4).
Classification of studies
Across the sample of 50 reviews from each cohort, data on the
single primary harm outcome were missing in 41% (486/1178)
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of the studies (407 included studies, 79 excluded studies; 375
randomised controlled trials, 111 non-randomised studies, fig
5⇓).
Table 2⇓ shows the classification of the 486 studies where the
single primary harm outcome data were either missing or
partially reported in the review (170 studies from the Cochrane
cohort and 316 from the adverse effect cohort). Nearly a fifth
of assessed studies (19%; 93/486) provided full data on the
single primary harm outcome of interest that was not included
in the review (table 2). Forty eight studies reported actual event
rates for each treatment arm or a suitable effect estimate with
a corresponding measure of precision, 23 specified that there
were no harms observed in the study, 21 specified there were
no actual events in the study concerning the single primary harm
outcome, and one reported the data in full in a way that was not
suitable for inclusion in the review analysis.
In nearly a third of studies assessed (32%, 126/393) where a
missing data classification was needed, it was clear that the
single review primary harm outcome was measured (P, Q, or R
classifications) but either not reported or partially reported. In
over half of the studies (53%, 208/393), it was likely that the
single review primary harm outcome was measured (S or T
classification) but not mentioned specifically. Outcome reporting
bias was suspected in 63% (248/393) of studies (P1, P2, R, and
S classifications).
Discussion
The principle findings of the study showed a high number of
reviews suspected of outcome reporting bias as a result of
missing or partially reported harm related outcomes. In this
study, an assessment of selective non-reporting of outcomes in
a review was required if one or more studies eligible for
inclusion in the review did not report data on the single review
primary harm outcome. An assessment was needed in 86% of
reviews in the Cochrane cohort and 76% of reviews in the
adverse event cohort. The proportion of reviews requiring
assessment for harm related outcomes was substantially higher
than that found in the previous Outcome Reporting Bias In
Trials (ORBIT) I study in which 55% (157/283) of Cochrane
reviews did not include full data for the single review primary
benefit outcome of interest from all eligible trials.3 In the ORBIT
I study, 31% of trials did not report on the primary benefit
outcome; this compares with 76% of the studies not reporting
on the single primary harm outcome from the Cochrane cohort
and 47% from the adverse event cohort. In ORBIT I, 50% of
trials (359/712) were under high suspicion of outcome reporting
bias, compared with 63% (248/393) in this study (P1, P2, R,
and S classifications). Readers of systematic reviews should be
aware that outcome reporting bias could potentially have an
important impact on the effect size estimates of adverse events.
Strengths and limitations of this study
The strengths of this study are that we evaluated two large
cohorts of reviews. Most reviews in the Cochrane cohort
quantified both the beneficial and the harmful effects of
healthcare interventions within the same review. The adverse
event cohort of reviews aimed specifically to synthesise studies
reporting on specific harms, which may have been longer term
harms. No reviews overlapped in the two cohorts (they stemmed
from non-overlapping time periods), and none of the studies
assessed for outcome reporting bias were included in multiple
reviews. Since non-randomised studies are often needed to
address questions about serious, rare, and long term harmful or
unintended effects, our classification system was developed to
encompass missing harms outcome data for both randomised
controlled trials and non-randomised studies. Review authors
or an expert in clinical pharmacology were involved in the
assessments, and a senior investigator checked a textual
justification for each classification. All assessments were
therefore carried out by a clinical expert and a non-clinical
methodologist. Importantly, more than two thirds of the reviews
assessed in the Cochrane cohort had input on classification from
the lead reviews. There was relatively less reviewer input for
the adverse event cohort, which is not unexpected given that
this cohort of reviews was slightly older.
In this study, we made a judgment as to whether the review
single primary harm outcome was measured or not based on all
the study references listed in the review. One way to improve
this judgment would be to obtain study protocols of eligible
studies to compare prespecified outcomes with those reported
in the final study reports. The comparison between what was
planned and assumed to be measured (in terms of outcome
specification) and what was actually reported (or not reported)
has the potential to simplify the classification of missing
outcome data.
We suspect that there are three aspects of this study that may
lead us to underestimate the extent of outcome reporting bias.
To adopt a similar approach to ORBIT I, we chose to look at
one primary review harm outcome for assessment from each
review. When choosing a single primary harm outcome, it is
possible that these were selected by the reviewers or
pharmacological expert because it was the particular harm that
was well recognised, important, serious, or common. This means
that the harm outcomes evaluated in our study would have been
less prone to outcome reporting bias. Hence our findings may
actually turn out to be an underestimate of the greater scale of
the problem. In practice, individual reviewers should complete
the assessment for all specified outcomes; this was not feasible
in our study because of the large cohort of reviews. Secondly,
the absence of references to excluded studies meant that nearly
half of the reviews in the adverse event cohort were excluded
because it was not possible for us to complete a full assessment
of outcome reporting bias. Although these exclusions were
unavoidable, we acknowledge that there may be greater
suspicion of outcome reporting bias in such reviews owing to
these excluded studies not reporting on any relevant outcome
data when compared with those reviews we were able to assess
within the same adverse events cohort. Finally, owing to the
high prevalence of reviews affected by missing single primary
harm outcome data, we were only able to fully assess a sample
of 50 reviews from each cohort of reviews. We do not suspect
that our sampling strategy will have impacted importantly on
the results of this study as the reviews were unselected in terms
of the type of harm, intervention, or population. However, if
there were more studies in any particular specialty, there might
be a greater expectation that specific harms would have been
measured, so the suspicion of outcome reporting bias would be
higher in the reviews we did not look at..
Implications for reporting harms in studies
of healthcare interventions
Many of the classifications for the partial or non-reporting of
harms data found in this study relate to poor reporting practice.
Better reporting of harms would provide timely and important
information to guide clinicians and the public in making
decisions about treatment not only at the individual study level
but also through allowing harms to be properly investigated in
systematic reviews and meta-analysis, which can have greater
statistical power from pooled data. We appreciate that many
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individual studies will be underpowered to detect significant
differences between groups for harm outcomes. Nevertheless,
it is important that these individual studies fully report on all
harms data, including “zero events” and harms that are rare.
To help monitor the complete reporting of harms (for
randomised controlled trials at least), researchers or independent
boards (sponsors, research ethics committees, or regulatory
authorities) must develop and implement plans to monitor and
report data for the safety of participants. The monitoring plan
should evaluate and report the incidence and severity of expected
harms to confirm that they match with those expected at the
initiation of the research. The incidence and causality of any
unanticipated or unexpected harms should also be closely
monitored and reported. Adherence to the CONSORT
(consolidating standards of reporting trials) extension for harms
11 or STROBE (strengthening the reporting of observational
studies in epidemiology)12 for non-randomised studies could
also greatly reduce the problem of poor reporting of harms.
Nevertheless, a recent review evaluating studies that have
examined the influence of the CONSORT for harms criteria has
shown that adverse events are poorly defined, with six of the
seven included studies demonstrating less than 50% adherence
to the items on the checklist.13 Journals should be more explicit
in their recommendations and expectations regarding the
endorsement of the CONSORT or STROBE statement and
related extensions (for example, CONSORT extension for
harms). Few journals recommend or require specific
endorsement of the CONSORT for harms statement in their
instructions for authors’ section.14
Implications for systematic reviews
The reliability of systematic reviews can be improved if more
attention is paid to specifying harm outcomes in a review. The
Cochrane handbook specifically states “There should in general
be nomore than three primary outcomes and they should include
at least one desirable and at least one undesirable outcome (to
assess beneficial and adverse effects, respectively).”15 Despite
such guidance nearly a fifth (17%) of newly published reviews
in the Cochrane cohort did not specify any harm outcomes, and
44% specified only pooled harms. This is only a marginal
improvement on the 24% (18/78) of Cochrane reviews published
in issue 1, 2005 that did not report on adverse events.6 In
addition, a recent study of 296 reviews identified from the
Database of Abstracts of Reviews of Effects revealed that nearly
a third of these reviews did not clearly define the adverse events
reviewed.16 It was not feasible to assess outcome reporting bias
in reviews that dealt with only pooled harms because there
would be no way to assess whether specific harms may have
been excluded from the eligible studies when calculating “all
harms.” Moreover, we discovered that nearly a fifth of studies
that underwent an assessment for outcome reporting bias had
actually provided full data (which had somehow been omitted
from the review) on the single primary harm outcome. We
strongly recommend that authors of systematic reviews pay
more attention to declaring the important harms for inclusion
in the review at the protocol stage. Extra care is required during
data extraction to ensure that reported outcomes data from
included studies is not missed; we also believe that for complete
transparency, data on zero events or no harms should also be
reported in reviews. In this study, any missing data on harms
from reviews that were found in study reports were fed back to
all review authors.
Studies should not be excluded from reviews because of having”
no relevant outcome data,” as the outcome data may be missing
as a direct result of selective outcome reporting.3 Nearly half
the reviews requiring assessment in the adverse event cohort
could not be assessed because studies were excluded for this
reason and no record was kept of the references to these
excluded studies.
The classification system used in this study has been presented
and applied during a workshop that we developed and delivered
at international Cochrane colloquiums. The feedback from this
workshop supported the practical application of our
classification system, and many participants were able to relate
their own experiences to the types of scenarios that are captured
in the classification. Following the application of the
classification system, the Cochrane risk of bias tool is currently
being updated to include the assessment of bias in both
randomised controlled trials and non-randomised studies. The
proposed new structure of the risk of bias tool considers selective
outcome reporting as being analogous to publication bias
(non-reporting of whole studies). It is planned that this form of
bias will be appraised outside the risk of bias tool (for example,
as part of the GRADE assessment in the summary of findings
tables).17 Our classification system does not confirm bias but
will help reviewers gain a better understanding of the reasons
for the lack of detail on harm reporting and which mechanisms
may be at high risk of bias. The implementation, writing of
guidelines, and Cochrane handbook chapters will include
guidance from both ORBIT I and ORBIT II; this should raise
the awareness of this problem for both benefit and harm
outcomes among the community of systematic review authors.
This in turn should improve the ability of decision makers to
make informed choices that consider both the benefits and the
harms of an intervention in an unbiased way, ultimately
improving patient safety.
Future research
The poor reporting of harms data in studies and systematic
reviews has implications for clinicians and patients because
there are difficulties in judging the benefit-risk trade-off when
much of the harms data is inadequately reported or not reported
at all. However, the mechanism for bias in harms reporting
remains unclear, although we are aware of a few potential
scenarios. This includes the conscious desire to avoid publishing
data that are unfavourable to a particular intervention. The
opposite is true if study authors make their own personal
judgment that particular adverse events are not serious or
unimportant and not significant, and therefore do not merit being
reported.
Owing to problemswith recall bias in the earlier interview study1
and because little emphasis was placed on harm outcomes, we
plan in future to interview trialists about differences between
outcomes specified in trial protocols and the trial report during
the peer review process to better understand mechanisms for
outcome reporting bias across both benefit and harm outcomes.
In partnership with The BMJ, we are conducting a pilot study
to determine the feasibility of carrying out such interviews. We
also plan to write a separate tutorial paper for assessing outcome
reporting bias in all benefit and harm outcomes for a single
review using the methods from ORBIT I and ORBIT II.
Conclusions
Our investigation found that many reviews were affected by
missing data on harms from at least one eligible study. We
suspected high risk of outcome reporting bias as the cause of
the missing data in over half the studies assessed. There is a
clear need to raise the awareness of both the existence and the
potential impact of bias when study authors measure harm
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outcomes and then to choose to either selectively not report the
findings or present the results in a way that cannot be reliably
used in a systematic review.
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What is already known on this topic
Empirical evidence suggests that the reporting of data on harms is likely to be less complete than that of benefit outcomes
Outcome reporting bias has previously been identified as a threat to evidence based medicine
Although previous research involving benefit outcomes has suggested that outcome reporting bias was suspected in at least one trial
in over a third of reviews, little is known about the prevalence of outcome reporting bias in harm outcomes
What this study adds
Outcome reporting bias for harms was evident in nearly two thirds of all primary studies included in systematic reviews
The reliability of systematic reviews can be improved if more attention is paid to specifying harm outcomes in a review
Studies should not be excluded from reviews because of having” no relevant outcome data,” as the outcome data may be missing as
a direct result of selective outcome reporting
Tables
Table 1| ORBIT II classification system
Risk of bias*Level of reportingDescriptionClassification
Explicit specific harm outcome
Measured and compared across treatment
groups:
High riskPartialStates outcome analysed but reported only that P>0.05P1
High riskPartialStates outcome analysed but reported only that P<0.05P2
Low riskPartialInsufficient reporting for meta-analysis or full tabulationP3
Measured but not compared across
treatment groups:
No riskNAClear that outcome was measured and clear outcome
was not compared
Q
Measured, not clear whether compared or
not across treatment groups†
High riskNoneClear that outcome was measured but no results
reported
R1
High riskNoneResult reported globally across all groupsR2
High riskNoneResult reported from some groups onlyR3
Specific harm outcome not explicitly mentioned
Clinical judgment says likely measured and
likely compared across treatment groups:
High riskNoneOnly pooled adverse events reported (could include
specific harm outcome)
S1
High riskNoneNo harms mentioned or reportedS2
Clinical judgment says likely measured but
no events:
Low riskNoneSpecific harm not mentioned but all other specific harms
fully reported
T1
Low riskNoneNo description of specific harmsT2
Specific harm outcome not explicitly mentioned, clinical judgment says unlikely measured
Low riskNoneNo harms mentioned or reportedU
Explicit the specific harm outcome was not measured
No riskNAReport clearly specifies that data on specific harm of
interest was not measured
V
NA=not applicable (clear that outcome was not going to be compared).
*Bias would occur if specific harm had been measured, but data were presented or suppressed in a way that would mask the harm profile of particular interventions.
†Clinical judgment says likely measured and likely compared across treatment groups.
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Table 2| Studies assessed for outcome reporting bias
Total No of studies
(%¶)










18 (4.6)5 (5.6)7 (4.1)0 (0.0)6 (4.8)P1
4 (1.0)4 (4.4)0 (0.0)0 (0.0)0 (0.0)P2
1 (0.3)1 (1.1)0 (0.0)0 (0.0)0 (0.0)P3
0 (0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Q
42 (10.7)16 (17.8)21 (12.2)0 (0.0)5 (4.0)R1
45 (11.5)13 (14.4)25 (14.5)0 (0.0)7 (5.6)R2
16 (4.1)4 (4.4)5 (2.9)0 (0.0)7 (5.6)R3
18 (4.6)4 (4.4)12 (7.0)0 (0.0)2 (1.6)S1
105 (26.7)24 (26.7)50 (29.1)0 (0.0)31 (24.8)S2
13 (3.3)2 (2.2)3 (1.7)3 (50.0)5 (4.0)T1
72 (18.3)1 (1.1)36 (20.9)0 (0.0)35 (28.0)T2
55 (14.0)13 (14.4)12 (7.0)3 (50.0)27 (21.6)U




*Calculated as percentage of total number of randomised controlled trials in Cochrane cohort (excluding full reporting) (n=125).
†Calculated as percentage of total number of non-randomised studies in Cochrane cohort (excluding full reporting) (n=6).
‡Calculated as percentage of total number of randomised controlled trials in adverse events cohort (excluding full reporting) (n=172).
§Calculated as percentage of total number of non-randomised studies in adverse events cohort (excluding full reporting) (n=90).
¶Calculated as percentage of total number of classifications (excluding full reporting) (n=393).
**Review primary harm outcome data reported in full in study report but not in review.
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Figures
Fig 1 Flow diagram for Cochrane cohort
Fig 2 Flow diagram for adverse event cohort
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Fig 3 Assessment of studies within reviews (Cochrane cohort)
Fig 4 Assessment of studies within reviews (adverse event cohort)
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Fig 5 Assessment of studies from sample of 50 reviews from each cohort
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